1
|
Sim HB, Sang Son J, Gupta SK, Jeong SH, Choi YJ, Han JY, Ramos SC, Kim H, Park DH, Yoo HJ, Yoo YJ, Chang DJ, Mun SK, Seo YH, Kim JJ. Development of Hsp90 inhibitor to regulate cytokine storms in excessive delayed- and acute inflammation. Int Immunopharmacol 2024; 137:112470. [PMID: 38908085 DOI: 10.1016/j.intimp.2024.112470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2024] [Revised: 06/09/2024] [Accepted: 06/10/2024] [Indexed: 06/24/2024]
Abstract
BACKGROUND The surplus cytokines remaining after use in the early stages of the inflammatory response stimulate immune cells even after the response is over, causing a secondary inflammatory response and ultimately damaging the host, which is called a cytokine storm. Inhibiting heat shock protein 90 (Hsp90), which has recently been shown to play an important role in regulating inflammation in various cell types, may help control excessive inflammatory responses and cytokine storms. METHODS We discovered an anti-inflammatory compound by measuring the inhibitory effect of CD86 expression on spleen DCs (sDCs) using the chemical compounds library of Hsp90 inhibitors. Subsequently, to select the hit compound, the production of cytokines and expression of surface molecules were measured on the bone marrow-derived DCs (BMDCs) and peritoneal macrophages. Then, we analyzed the response of antigen-specific Th1 cells. Finally, we confirmed the effect of the compound using acute lung injury (ALI) and delayed-type hypersensitivity (DTH) models. RESULTS We identified Be01 as the hit compound, which reduced CD86 expression the most in sDCs. Treatment with Be01 decreased the production of pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) in BMDC and peritoneal macrophages stimulated by LPS. Under the DTH model, Be01 treatment reduced ear swelling and pro-inflammatory cytokines in the spleen. Similarly, Be01 treatment in the ALI model decreased neutrophil infiltration and lower levels of secreted cytokines (IL-6, TNF-α). CONCLUSIONS Reduction of CD80 and CD86 expression on DCs by Be01 indicates reduced secondary inflammatory response by Th1 cells, and reduced release of pro-inflammatory cytokines by peritoneal macrophages may initially control the cytokine storm.
Collapse
Affiliation(s)
- Hyun Bo Sim
- Department of Biomedical Science, Sunchon National University, 255 Jungang-Ro, Suncheon 57922, Republic of Korea
| | - Jun Sang Son
- Department of Biomedical Science, Sunchon National University, 255 Jungang-Ro, Suncheon 57922, Republic of Korea
| | - Sunil K Gupta
- College of Pharmacy, Keimyung University, Daegu 704-701, Republic of Korea
| | - Seung-Hyun Jeong
- Department of Pharmacy, College of Pharmacy, Sunchon National University, 255 Jungang-Ro, Suncheon 57922, Republic of Korea
| | - Yu-Jeong Choi
- Department of Biomedical Science, Sunchon National University, 255 Jungang-Ro, Suncheon 57922, Republic of Korea
| | - Ji Yeon Han
- Department of Biomedical Science, Sunchon National University, 255 Jungang-Ro, Suncheon 57922, Republic of Korea
| | - Sonny C Ramos
- Department of Biomedical Science, Sunchon National University, 255 Jungang-Ro, Suncheon 57922, Republic of Korea
| | - Hyeongyeong Kim
- Department of Biomedical Science, Sunchon National University, 255 Jungang-Ro, Suncheon 57922, Republic of Korea
| | - Dae-Han Park
- Department of Biomedical Science, Sunchon National University, 255 Jungang-Ro, Suncheon 57922, Republic of Korea
| | - Ho Jin Yoo
- Department of Biomedical Science, Sunchon National University, 255 Jungang-Ro, Suncheon 57922, Republic of Korea
| | - Young Joo Yoo
- Department of Biomedical Science, Sunchon National University, 255 Jungang-Ro, Suncheon 57922, Republic of Korea
| | - Dong-Jo Chang
- Department of Pharmacy, College of Pharmacy, Sunchon National University, 255 Jungang-Ro, Suncheon 57922, Republic of Korea
| | - Seul-Ki Mun
- Department of Biomedical Science, Sunchon National University, 255 Jungang-Ro, Suncheon 57922, Republic of Korea.
| | - Young Ho Seo
- College of Pharmacy, Keimyung University, Daegu 704-701, Republic of Korea.
| | - Jong-Jin Kim
- Department of Biomedical Science, Sunchon National University, 255 Jungang-Ro, Suncheon 57922, Republic of Korea.
| |
Collapse
|
2
|
Romero‐Castillo L, Li T, Do N, Sareila O, Xu B, Hennings V, Xu Z, Svensson C, Oliveira‐Coelho A, Sener Z, Urbonaviciute V, Ekwall O, Burkhardt H, Holmdahl R. Human MHC Class II and Invariant Chain Knock-in Mice Mimic Rheumatoid Arthritis with Allele Restriction in Immune Response and Arthritis Association. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2024; 11:e2401513. [PMID: 38602454 PMCID: PMC11187888 DOI: 10.1002/advs.202401513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/11/2024] [Indexed: 04/12/2024]
Abstract
Transgenic mice expressing human major histocompatibility complex class II (MHCII) risk alleles are widely used in autoimmune disease research, but limitations arise due to non-physiologic expression. To address this, physiologically relevant mouse models are established via knock-in technology to explore the role of MHCII in diseases like rheumatoid arthritis. The gene sequences encoding the ectodomains are replaced with the human DRB1*04:01 and 04:02 alleles, DRA, and CD74 (invariant chain) in C57BL/6N mice. The collagen type II (Col2a1) gene is modified to mimic human COL2. Importantly, DRB1*04:01 knock-in mice display physiologic expression of human MHCII also on thymic epithelial cells, in contrast to DRB1*04:01 transgenic mice. Humanization of the invariant chain enhances MHCII expression on thymic epithelial cells, increases mature B cell numbers in spleen, and improves antigen presentation. To validate its functionality, the collagen-induced arthritis (CIA) model is used, where DRB1*04:01 expression led to a higher susceptibility to arthritis, as compared with mice expressing DRB1*04:02. In addition, the humanized T cell epitope on COL2 allows autoreactive T cell-mediated arthritis development. In conclusion, the humanized knock-in mouse faithfully expresses MHCII, confirming the DRB1*04:01 alleles role in rheumatoid arthritis and being also useful for studying MHCII-associated diseases.
Collapse
MESH Headings
- Animals
- Mice
- Arthritis, Rheumatoid/genetics
- Arthritis, Rheumatoid/immunology
- Antigens, Differentiation, B-Lymphocyte/genetics
- Antigens, Differentiation, B-Lymphocyte/immunology
- Humans
- Disease Models, Animal
- Mice, Inbred C57BL
- Mice, Transgenic
- Gene Knock-In Techniques/methods
- Histocompatibility Antigens Class II/genetics
- Histocompatibility Antigens Class II/immunology
- Alleles
- Arthritis, Experimental/genetics
- Arthritis, Experimental/immunology
- HLA-DRB1 Chains/genetics
- HLA-DRB1 Chains/immunology
- Collagen Type II/genetics
- Collagen Type II/immunology
Collapse
Affiliation(s)
- Laura Romero‐Castillo
- Medical Inflammation ResearchDivision of ImmunologyDepartment of Medical Biochemistry and BiophysicsKarolinska InstituteStockholm17177Sweden
| | - Taotao Li
- Medical Inflammation ResearchDivision of ImmunologyDepartment of Medical Biochemistry and BiophysicsKarolinska InstituteStockholm17177Sweden
| | - Nhu‐Nguyen Do
- Medical Inflammation ResearchDivision of ImmunologyDepartment of Medical Biochemistry and BiophysicsKarolinska InstituteStockholm17177Sweden
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMPFraunhofer Cluster of Excellence for Immune‐Mediated Diseases CIMDTheodor‐Stern‐Kai 760596Frankfurt am MainGermany
| | - Outi Sareila
- Medical Inflammation ResearchDivision of ImmunologyDepartment of Medical Biochemistry and BiophysicsKarolinska InstituteStockholm17177Sweden
- Medical Inflammation ResearchMediCity Research LaboratoryUniversity of TurkuTurkuFI‐20520Finland
| | - Bingze Xu
- Medical Inflammation ResearchDivision of ImmunologyDepartment of Medical Biochemistry and BiophysicsKarolinska InstituteStockholm17177Sweden
| | - Viktoria Hennings
- Department of PediatricsInstitute of Clinical Sciences and Department of Rheumatology and Inflammation ResearchInstitute of MedicineThe Sahlgrenska AcademyUniversity of GothenburgGothenburg41345Sweden
| | - Zhongwei Xu
- Medical Inflammation ResearchDivision of ImmunologyDepartment of Medical Biochemistry and BiophysicsKarolinska InstituteStockholm17177Sweden
| | - Carolin Svensson
- Medical Inflammation ResearchDivision of ImmunologyDepartment of Medical Biochemistry and BiophysicsKarolinska InstituteStockholm17177Sweden
| | - Ana Oliveira‐Coelho
- Medical Inflammation ResearchDivision of ImmunologyDepartment of Medical Biochemistry and BiophysicsKarolinska InstituteStockholm17177Sweden
| | - Zeynep Sener
- Medical Inflammation ResearchDivision of ImmunologyDepartment of Medical Biochemistry and BiophysicsKarolinska InstituteStockholm17177Sweden
| | - Vilma Urbonaviciute
- Medical Inflammation ResearchDivision of ImmunologyDepartment of Medical Biochemistry and BiophysicsKarolinska InstituteStockholm17177Sweden
| | - Olov Ekwall
- Department of PediatricsInstitute of Clinical Sciences and Department of Rheumatology and Inflammation ResearchInstitute of MedicineThe Sahlgrenska AcademyUniversity of GothenburgGothenburg41345Sweden
| | - Harald Burkhardt
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMPFraunhofer Cluster of Excellence for Immune‐Mediated Diseases CIMDTheodor‐Stern‐Kai 760596Frankfurt am MainGermany
- Division of RheumatologyUniversity Hospital FrankfurtGoethe University60590Frankfurt am MainGermany
| | - Rikard Holmdahl
- Medical Inflammation ResearchDivision of ImmunologyDepartment of Medical Biochemistry and BiophysicsKarolinska InstituteStockholm17177Sweden
- Medical Inflammation ResearchMediCity Research LaboratoryUniversity of TurkuTurkuFI‐20520Finland
| |
Collapse
|
3
|
James J, Coelho A, Lahore GF, Hernandez CM, Forster F, Malissen B, Holmdahl R. Redox Regulation of LAT Enhances T Cell-Mediated Inflammation. Antioxidants (Basel) 2024; 13:499. [PMID: 38671946 PMCID: PMC11047684 DOI: 10.3390/antiox13040499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Revised: 04/04/2024] [Accepted: 04/07/2024] [Indexed: 04/28/2024] Open
Abstract
The positional cloning of single nucleotide polymorphisms (SNPs) of the neutrophil cytosolic factor 1 (Ncf1) gene, advocating that a low oxidative burst drives autoimmune disease, demands an understanding of the underlying molecular causes. A cellular target could be T cells, which have been shown to be regulated by reactive oxygen species (ROS). However, the pathways by which ROS mediate T cell signaling remain unclear. The adaptor molecule linker for activation of T cells (LAT) is essential for coupling T cell receptor-mediated antigen recognition to downstream responses, and it contains several cysteine residues that have previously been suggested to be involved in redox regulation. To address the possibility that ROS regulate T cell-dependent inflammation through LAT, we established a mouse strain with cysteine-to-serine mutations at positions 120 and 172 (LATSS). We found that redox regulation of LAT through C120 and C172 mediate its localization and phosphorylation. LATSS mice had reduced numbers of double-positive thymocytes and naïve peripheral T cells. Importantly, redox insensitivity of LAT enhanced T cell-dependent autoimmune inflammation in collagen-induced arthritis (CIA), a mouse model of rheumatoid arthritis (RA). This effect was reversed on an NCF1-mutated (NCF1m1j), ROS-deficient, background. Overall, our data show that LAT is redox-regulated, acts to repress T cell activation, and is targeted by ROS induced by NCF1 in antigen-presenting cells (APCs).
Collapse
Affiliation(s)
- Jaime James
- Medical Inflammation Research, Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden; (J.J.); (A.C.); (G.F.L.); (C.M.H.); (F.F.)
| | - Ana Coelho
- Medical Inflammation Research, Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden; (J.J.); (A.C.); (G.F.L.); (C.M.H.); (F.F.)
| | - Gonzalo Fernandez Lahore
- Medical Inflammation Research, Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden; (J.J.); (A.C.); (G.F.L.); (C.M.H.); (F.F.)
| | - Clara M. Hernandez
- Medical Inflammation Research, Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden; (J.J.); (A.C.); (G.F.L.); (C.M.H.); (F.F.)
| | - Florian Forster
- Medical Inflammation Research, Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden; (J.J.); (A.C.); (G.F.L.); (C.M.H.); (F.F.)
| | - Bernard Malissen
- Centre d’Immunophénomique, Aix Marseille Université, INSERM, 13288 Marseille, France;
| | - Rikard Holmdahl
- Medical Inflammation Research, Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden; (J.J.); (A.C.); (G.F.L.); (C.M.H.); (F.F.)
| |
Collapse
|
4
|
Pradenas C, Luque-Campos N, Oyarce K, Contreras-Lopez R, Bustamante-Barrientos FA, Bustos A, Galvez-Jiron F, Araya MJ, Asencio C, Lagos R, Herrera-Luna Y, Abba Moussa D, Hill CN, Lara-Barba E, Altamirano C, Ortloff A, Hidalgo-Fadic Y, Vega-Letter AM, García-Robles MDLÁ, Djouad F, Luz-Crawford P, Elizondo-Vega R. Lactate: an alternative pathway for the immunosuppressive properties of mesenchymal stem/stromal cells. Stem Cell Res Ther 2023; 14:335. [PMID: 37981698 PMCID: PMC10659074 DOI: 10.1186/s13287-023-03549-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Accepted: 10/27/2023] [Indexed: 11/21/2023] Open
Abstract
BACKGROUND The metabolic reprogramming of mesenchymal stem/stromal cells (MSC) favoring glycolysis has recently emerged as a new approach to improve their immunotherapeutic abilities. This strategy is associated with greater lactate release, and interestingly, recent studies have proposed lactate as a functional suppressive molecule, changing the old paradigm of lactate as a waste product. Therefore, we evaluated the role of lactate as an alternative mediator of MSC immunosuppressive properties and its contribution to the enhanced immunoregulatory activity of glycolytic MSCs. MATERIALS AND METHODS Murine CD4+ T cells from C57BL/6 male mice were differentiated into proinflammatory Th1 or Th17 cells and cultured with either L-lactate, MSCs pretreated or not with the glycolytic inductor, oligomycin, and MSCs pretreated or not with a chemical inhibitor of lactate dehydrogenase A (LDHA), galloflavin or LDH siRNA to prevent lactate production. Additionally, we validated our results using human umbilical cord-derived MSCs (UC-MSCs) in a murine model of delayed type 1 hypersensitivity (DTH). RESULTS Our results showed that 50 mM of exogenous L-lactate inhibited the proliferation rate and phenotype of CD4+ T cell-derived Th1 or Th17 by 40% and 60%, respectively. Moreover, the suppressive activity of both glycolytic and basal MSCs was impaired when LDH activity was reduced. Likewise, in the DTH inflammation model, lactate production was required for MSC anti-inflammatory activity. This lactate dependent-immunosuppressive mechanism was confirmed in UC-MSCs through the inhibition of LDH, which significantly decreased their capacity to control proliferation of activated CD4+ and CD8+ human T cells by 30%. CONCLUSION These findings identify a new MSC immunosuppressive pathway that is independent of the classical suppressive mechanism and demonstrated that the enhanced suppressive and therapeutic abilities of glycolytic MSCs depend at least in part on lactate production.
Collapse
Affiliation(s)
- Carolina Pradenas
- Laboratorio de Biología Celular, Departamento de Biología Celular, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile
- Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile
| | - Noymar Luque-Campos
- Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile
- IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile
| | - Karina Oyarce
- Facultad de Medicina y Ciencia, Universidad San Sebastián, Concepción, Chile
| | | | - Felipe A Bustamante-Barrientos
- Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile
- IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile
| | - Andrés Bustos
- Laboratorio de Biología Celular, Departamento de Biología Celular, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile
| | - Felipe Galvez-Jiron
- Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile
| | - María Jesús Araya
- Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile
- IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile
| | - Catalina Asencio
- Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile
- IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile
- Millennium Institute on Immunology and Immunotherapy, Santiago, Chile
| | - Raúl Lagos
- Laboratorio de Biología Celular, Departamento de Biología Celular, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile
| | - Yeimi Herrera-Luna
- Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile
- IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile
| | | | - Charlotte Nicole Hill
- Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile
- Millennium Institute on Immunology and Immunotherapy, Santiago, Chile
| | - Eliana Lara-Barba
- Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile
- IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile
| | - Claudia Altamirano
- IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile
- Escuela de Ingeniería Bioquímica, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile
| | - Alexander Ortloff
- Departamento de Ciencias Veterinarias y Salud Pública, Facultad de Recursos Naturales, Universidad Católica de Temuco, Temuco, Chile
| | - Yessia Hidalgo-Fadic
- IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile
| | - Ana María Vega-Letter
- Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile
- Escuela de Ingeniería Bioquímica, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile
| | - María de Los Ángeles García-Robles
- Laboratorio de Biología Celular, Departamento de Biología Celular, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile
| | - Farida Djouad
- IRMB, University of Montpellier, INSERM, 34295, Montpellier, France.
- Clinical Immunology and Osteoarticular Disease Therapeutic Unit, Department of Rheumatology, CHU Montpellier, 34095, Montpellier, France.
| | - Patricia Luz-Crawford
- Centro de Investigación Biomédica, Facultad de Medicina, Universidad de Los Andes, Santiago, Chile.
- IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile.
| | - Roberto Elizondo-Vega
- Laboratorio de Biología Celular, Departamento de Biología Celular, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción, Chile.
| |
Collapse
|
5
|
Pseurotin D inhibits delayed type IV hypersensitivity response. Chem Biol Interact 2022; 368:110241. [DOI: 10.1016/j.cbi.2022.110241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2022] [Revised: 10/14/2022] [Accepted: 10/24/2022] [Indexed: 11/18/2022]
|
6
|
Topping LM, Romero-Castillo L, Urbonaviciute V, Bolinsson H, Clanchy FI, Holmdahl R, Bäckström BT, Williams RO. Standardization of Antigen-Emulsion Preparations for the Induction of Autoimmune Disease Models. Front Immunol 2022; 13:892251. [PMID: 35769487 PMCID: PMC9234561 DOI: 10.3389/fimmu.2022.892251] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Accepted: 05/18/2022] [Indexed: 11/15/2022] Open
Abstract
Autoimmune murine disease models are vital tools for identifying novel targets and finding better treatments for human diseases. Complete Freund’s adjuvant is commonly used to induce disease in autoimmune models, and the quality of the adjuvant/autoantigen emulsion is of critical importance in determining reproducibility. We have established an emulsification method using a standard homogenizer and specially designed receptacle. Emulsions are easy to prepare, form stable and uniform water-in-oil particles, are faster to make than the traditional syringe method, use less material and are designed to fill syringes with ease. In the present study, we have validated the emulsions for induction of experimental autoimmune encephalitis, collagen II induced arthritis, antigen induced arthritis, and delayed type hypersensitivity models. These models were induced consistently and reproducibly and, in some cases, the new method outperformed the traditional method. The method described herein is simple, cost-effective and will reduce variability, thereby requiring fewer animals for in vivo research involving animal models of autoimmune disease and in vaccine development.
Collapse
Affiliation(s)
- Louise M. Topping
- Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
| | - Laura Romero-Castillo
- Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
| | - Vilma Urbonaviciute
- Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
| | - Hans Bolinsson
- Department of Food Technology, Engineering and Nutrition, Lund University, Lund, Sweden
| | - Felix I. Clanchy
- Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
- Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
| | - Rikard Holmdahl
- Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
| | - B. Thomas Bäckström
- The Rausing Laboratory, Division of Neurosurgery, Department of Clinical Sciences, Lund University, Lund, Sweden
- Department of Autoimmunity, BTB Emulsions AB, Malmo, Sweden
- *Correspondence: B. Thomas Bäckström,
| | - Richard O. Williams
- Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
| |
Collapse
|
7
|
James J, Chen Y, Hernandez CM, Forster F, Dagnell M, Cheng Q, Saei AA, Gharibi H, Lahore GF, Åstrand A, Malhotra R, Malissen B, Zubarev RA, Arnér ESJ, Holmdahl R. Redox regulation of PTPN22 affects the severity of T-cell-dependent autoimmune inflammation. eLife 2022; 11:74549. [PMID: 35587260 PMCID: PMC9119677 DOI: 10.7554/elife.74549] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Accepted: 03/16/2022] [Indexed: 12/16/2022] Open
Abstract
Chronic autoimmune diseases are associated with mutations in PTPN22, a modifier of T cell receptor (TCR) signaling. As with all protein tyrosine phosphatases, the activity of PTPN22 is redox regulated, but if or how such regulation can modulate inflammatory pathways in vivo is not known. To determine this, we created a mouse with a cysteine-to-serine mutation at position 129 in PTPN22 (C129S), a residue proposed to alter the redox regulatory properties of PTPN22 by forming a disulfide with the catalytic C227 residue. The C129S mutant mouse showed a stronger T-cell-dependent inflammatory response and development of T-cell-dependent autoimmune arthritis due to enhanced TCR signaling and activation of T cells, an effect neutralized by a mutation in Ncf1, a component of the NOX2 complex. Activity assays with purified proteins suggest that the functional results can be explained by an increased sensitivity to oxidation of the C129S mutated PTPN22 protein. We also observed that the disulfide of native PTPN22 can be directly reduced by the thioredoxin system, while the C129S mutant lacking this disulfide was less amenable to reductive reactivation. In conclusion, we show that PTPN22 functionally interacts with Ncf1 and is regulated by oxidation via the noncatalytic C129 residue and oxidation-prone PTPN22 leads to increased severity in the development of T-cell-dependent autoimmunity.
Collapse
Affiliation(s)
- Jaime James
- Division of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
| | - Yifei Chen
- Division of Biochemistry, Dept. of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.,Department of Gastroenterology, the First Affiliated Hospital of Xi'an Jiaotong University, Shaanxi, China
| | - Clara M Hernandez
- Division of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
| | - Florian Forster
- Division of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
| | - Markus Dagnell
- Division of Biochemistry, Dept. of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
| | - Qing Cheng
- Division of Biochemistry, Dept. of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
| | - Amir A Saei
- Division of Physiological Chemistry I, Dept. of Medical Biochemistry and Biophysics Karolinska Institute, Stockholm, Sweden.,Department of Cell Biology, Harvard Medical School, Boston, United States
| | - Hassan Gharibi
- Division of Physiological Chemistry I, Dept. of Medical Biochemistry and Biophysics Karolinska Institute, Stockholm, Sweden
| | - Gonzalo Fernandez Lahore
- Division of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
| | - Annika Åstrand
- Project Leader Department, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Rajneesh Malhotra
- Translational Science and Experimental Medicine, Research and Early Development Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Bernard Malissen
- Centre d'Immunophénomique, Aix Marseille Université, INSERM, Marseille, France
| | - Roman A Zubarev
- Division of Physiological Chemistry I, Dept. of Medical Biochemistry and Biophysics Karolinska Institute, Stockholm, Sweden.,Department of Pharmacological & Technological Chemistry, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
| | - Elias S J Arnér
- Division of Biochemistry, Dept. of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden.,Department of Selenoprotein Research, National Institute of Oncology, Budapest, Hungary
| | - Rikard Holmdahl
- Division of Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.,National and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| |
Collapse
|
8
|
Astaxanthin Mitigates Thiacloprid-Induced Liver Injury and Immunotoxicity in Male Rats. Mar Drugs 2021; 19:md19090525. [PMID: 34564187 PMCID: PMC8467938 DOI: 10.3390/md19090525] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 09/15/2021] [Accepted: 09/16/2021] [Indexed: 12/18/2022] Open
Abstract
Thiacloprid (TCP) is a widely used neonicotinoid insecticide with a probable toxic hazard to animals and human beings. This hazard has intensified the demand for natural compounds to alleviate the expected toxic insults. This study aimed at determining whether astaxanthin (ASX) could mitigate the hepatotoxic effect of TCP and diminish its suppressive effect on immune responses in rats. Animals received TCP by gavage at 62.1 mg/kg (1/10th LD50) with or without ASX at 40 mg/kg for 60 days. Intoxicated rats showed modulation of serum transaminases and protein profiles. The hemagglutination antibody titer to sheep red blood cells (SRBC) and the number of plaque-forming cells in the spleen were reduced. The cell-mediated immunity and phagocytosis were suppressed, while serum interleukins IL-1β, IL-6, and IL-10 were elevated. Additionally, malondialdehyde, nitric oxide, and 8-hydroxy-2'-deoxyguanosine levels were increased in the liver, spleen, and thymus, with depletion of glutathione and suppression of superoxide dismutase and catalase activities. The expressions of inducible nitric oxide synthase and the high mobility group box protein 1 genes were upregulated with histomorphological alterations in the aforementioned organs. Cotreatment with ASX markedly ameliorated the toxic effects of TCP, and all markers showed a regression trend towards control values. Collectively, our data suggest that the protective effects of ASX on the liver and immune system of TCP-treated animals depend upon improving the antioxidant status and relieving the inflammatory response, and thus it may be used as a promising therapeutic agent to provide superior hepato- and immunoprotection.
Collapse
|
9
|
Bilyy R, Pagneux Q, François N, Bila G, Grytsko R, Lebedin Y, Barras A, Dubuisson J, Belouzard S, Séron K, Boukherroub R, Szunerits S. Rapid Generation of Coronaviral Immunity Using Recombinant Peptide Modified Nanodiamonds. Pathogens 2021; 10:861. [PMID: 34358011 PMCID: PMC8308543 DOI: 10.3390/pathogens10070861] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Revised: 06/27/2021] [Accepted: 06/28/2021] [Indexed: 12/29/2022] Open
Abstract
Vaccination remains one of the most effective tools to prevent infectious diseases. To ensure that the best possible antigenic components are chosen to stimulate a cognitive immune response, boosting antigen presentation using adjuvants is common practice. Nanodiamond-based adjuvants are proposed here as a rapid and versatile platform for antigen conjugation, utilizing peptides common to different pathogenic strains and making this strategy a good candidate for a "ready-to-use" vaccine. Initiation of an inflammatory reaction with a resulting immune response is based on the ability of living organisms to entrap nanostructures such as nanodiamonds with neutrophil extracellular traps (NETs) formation. In this work, coronavirus peptide homological for MERS-CoV, fusion inhibitor, was conjugated to nanodiamonds and used to induce neutrophilic-driven self-limiting inflammation. The resulting adjuvant was safe and did not induce any tissue damage at the site of injection. Mice immunization resulted in IgG titers of ¼,000 within 28 days. Immunization of rabbits resulted in the formation of a high level of antibodies persistently present for up to 120 days after the first immunization (animal lifespan ~3 years). The peptide used for immunization proved to be reactive with sera of convalescent COVID patients, demonstrating the possibility of developing pancoronaviral vaccine candidates.
Collapse
Affiliation(s)
- Rostyslav Bilyy
- Danylo Halytsky Lviv National Medical University, Pekarska Str., 69, 79010 Lviv, Ukraine; (G.B.); (R.G.)
| | - Quentin Pagneux
- University of Lille, CNRS, Centrale Lille, University Polytechnique Hauts-de-France, UMR 8520-IEMN, F-59000 Lille, France; (Q.P.); (A.B.); (R.B.)
| | - Nathan François
- U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS, INSERM, CHU Lille, F-59000 Lille, France; (N.F.); (J.D.); (S.B.); (K.S.)
| | - Galyna Bila
- Danylo Halytsky Lviv National Medical University, Pekarska Str., 69, 79010 Lviv, Ukraine; (G.B.); (R.G.)
| | - Roman Grytsko
- Danylo Halytsky Lviv National Medical University, Pekarska Str., 69, 79010 Lviv, Ukraine; (G.B.); (R.G.)
| | - Yuri Lebedin
- Xema Co., Ltd., Akademika Efremova Str., 23, 03179 Kyiv, Ukraine;
| | - Alexandre Barras
- University of Lille, CNRS, Centrale Lille, University Polytechnique Hauts-de-France, UMR 8520-IEMN, F-59000 Lille, France; (Q.P.); (A.B.); (R.B.)
| | - Jean Dubuisson
- U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS, INSERM, CHU Lille, F-59000 Lille, France; (N.F.); (J.D.); (S.B.); (K.S.)
| | - Sandrine Belouzard
- U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS, INSERM, CHU Lille, F-59000 Lille, France; (N.F.); (J.D.); (S.B.); (K.S.)
| | - Karin Séron
- U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Institut Pasteur de Lille, University of Lille, CNRS, INSERM, CHU Lille, F-59000 Lille, France; (N.F.); (J.D.); (S.B.); (K.S.)
| | - Rabah Boukherroub
- University of Lille, CNRS, Centrale Lille, University Polytechnique Hauts-de-France, UMR 8520-IEMN, F-59000 Lille, France; (Q.P.); (A.B.); (R.B.)
| | - Sabine Szunerits
- University of Lille, CNRS, Centrale Lille, University Polytechnique Hauts-de-France, UMR 8520-IEMN, F-59000 Lille, France; (Q.P.); (A.B.); (R.B.)
| |
Collapse
|
10
|
Li M, Yu H. Identification of WP1066, an inhibitor of JAK2 and STAT3, as a K V 1.3 potassium channel blocker. Br J Pharmacol 2021; 178:2617-2631. [PMID: 33689167 DOI: 10.1111/bph.15441] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 01/15/2021] [Accepted: 02/09/2021] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND AND PURPOSE KV 1.3 potassium channels play a predominant role in regulating calcium signalling that is essential for the activation and proliferation of effector memory T (TEM ) cells. This ion channel has been recognized as a promising therapeutic target against various autoimmune diseases. EXPERIMENTAL APPROACH In a high-throughput screening programme, WP1066 was identified as a KV 1.3 channel inhibitor. Using molecular biology and electrophysiological methods, the mechanism(s) underlying WP1066 blockade of Kv1.3 channels was investigated. Using TEM cell proliferation assay and mouse delayed-type hypersensitivity (DTH) model, the effects of WP1066 were examined. KEY RESULTS WP1066 blocked KV 1.3 channels in a dose-dependent manner with an IC50 of 3.2 μM and induced a hyperpolarizing shift of the steady-state inactivation curve. This blockade was use-dependent, as WP1066 interacted preferentially with channels in their open state, rather than the closed state or inactivated state. When the residues located in the S6 domain scaffolding the inner vestibule, were sequentially mutated, the potency of WP1066 was significantly impaired, especially by mutations A413C and I420C, indicating a higher affinity of interacting sites for WP1066. Moreover, WP1066 effectively suppressed mouse TEM cell proliferation in vitro and mouse DTH reaction in vivo. CONCLUSIONS AND IMPLICATIONS The results presented here have identified WP1066 as a KV 1.3 channel blocker with an open-state-dependent property, providing fundamental evidence for the application of WP1066 in further immunomodulatory studies targeting KV 1.3 channels.
Collapse
Affiliation(s)
- Min Li
- State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Haibo Yu
- State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|
11
|
HIF-1α and Pro-Inflammatory Signaling Improves the Immunomodulatory Activity of MSC-Derived Extracellular Vesicles. Int J Mol Sci 2021; 22:ijms22073416. [PMID: 33810359 PMCID: PMC8036951 DOI: 10.3390/ijms22073416] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 03/23/2021] [Accepted: 03/24/2021] [Indexed: 02/07/2023] Open
Abstract
Despite the strong evidence for the immunomodulatory activity of mesenchymal stromal cells (MSCs), clinical trials have so far failed to clearly show benefit, likely reflecting methodological shortcomings and lack of standardization. MSC-mediated tissue repair is commonly believed to occur in a paracrine manner, and it has been stated that extracellular vesicles (EVs) secreted by MSCs (EVMSC) are able to recapitulate the immunosuppressive properties of parental cells. As a next step, clinical trials to corroborate preclinical studies should be performed. However, effective dose in large mammals, including humans, is quite high and EVs industrial production is hindered by the proliferative senescence that affects MSCs during massive cell expansion. We generated a genetically modified MSC cell line overexpressing hypoxia-inducible factor 1-alpha and telomerase to increase the therapeutic potency of EVMSC and facilitate their large-scale production. We also developed a cytokine-based preconditioning culture medium to prime the immunomodulatory response of secreted EVs (EVMSC-T-HIFc). We tested the efficacy of this system in vitro and in a delayed-type hypersensitivity mouse model. MSC-T with an HIF-1α-GFP lentiviral vector (MSC-T-HIF) can be effectively expanded to obtain large amounts of EVs without major changes in cell phenotype and EVs composition. EVMSC-T-HIFc suppressed the proliferation of activated T-cells more effectively than did EVs from unmodified MSC in vitro, and significantly blunted the ear-swelling response in vivo by inhibiting cell infiltration and improving tissue integrity. We have developed a long-lived EV source that secretes high quantities of immunosuppressive EVs, facilitating a more standard and cost-effective therapeutic product.
Collapse
|
12
|
Placental growth factor regulates the generation of T H17 cells to link angiogenesis with autoimmunity. Nat Immunol 2019; 20:1348-1359. [PMID: 31406382 DOI: 10.1038/s41590-019-0456-4] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2018] [Accepted: 06/28/2019] [Indexed: 02/06/2023]
Abstract
Helper T cells actively communicate with adjacent cells by secreting soluble mediators, yet crosstalk between helper T cells and endothelial cells remains poorly understood. Here we found that placental growth factor (PlGF), a homolog of the vascular endothelial growth factor that enhances an angiogenic switch in disease, was selectively secreted by the TH17 subset of helper T cells and promoted angiogenesis. Interestingly, the 'angio-lymphokine' PlGF, in turn, specifically induced the differentiation of pathogenic TH17 cells by activating the transcription factor STAT3 via binding to its receptors and replaced the activity of interleukin-6 in the production of interleukin-17, whereas it suppressed the generation of regulatory T cells. Moreover, T cell-derived PlGF was required for the progression of autoimmune diseases associated with TH17 differentiation, including experimental autoimmune encephalomyelitis and collagen-induced arthritis, in mice. Collectively, our findings provide insights into the PlGF-dictated links among angiogenesis, TH17 cell development and autoimmunity.
Collapse
|
13
|
Paryzhak SY, Dumych TI, Peshkova SM, Bila EE, Lutsyk AD, Barras A, Boukherroub R, Szunerits S, Bilyy RO. Interaction of 4 allotropic modifications of carbon nanoparticles with living tissues. UKRAINIAN BIOCHEMICAL JOURNAL 2019. [DOI: 10.15407/ubj91.02.041] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
14
|
NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. Nat Commun 2018; 9:5014. [PMID: 30479396 PMCID: PMC6258697 DOI: 10.1038/s41467-018-07452-y] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Accepted: 10/31/2018] [Indexed: 12/30/2022] Open
Abstract
Neurofibromatosis type 1 (NF1) is an autosomal genetic disorder. Patients with NF1 are associated with mono-allelic loss of the tumor suppressor gene NF1 in their germline, which predisposes them to develop a wide array of benign lesions. Intriguingly, recent sequencing efforts revealed that the NF1 gene is frequently mutated in multiple malignant tumors not typically associated with NF1 patients, suggesting that NF1 heterozygosity is refractory to at least some cancer types. In two orthogonal mouse models representing NF1- and non-NF1-related tumors, we discover that an Nf1+/− microenvironment accelerates the formation of benign tumors but impairs further progression to malignancy. Analysis of benign and malignant tumors commonly associated with NF1 patients, as well as those with high NF1 gene mutation frequency, reveals an antagonistic role for NF1 heterozygosity in tumor initiation and malignant transformation and helps to reconciliate the role of the NF1 gene in both NF1 and non-NF1 patient contexts. Germline mono-allelic loss of the tumour suppressor NF1 predisposes patients to the development of benign lesions but rarely further progression into cancer development. Here the authors use mouse models to show that an NF1 heterozygous microenvironment accelerates the formation of benign tumours but impairs progression to malignancy.
Collapse
|
15
|
Francisconi C, Vieira A, Azevedo M, Tabanez A, Fonseca A, Trombone A, Letra A, Silva R, Sfeir C, Little S, Garlet G. RANKL Triggers Treg-Mediated Immunoregulation in Inflammatory Osteolysis. J Dent Res 2018; 97:917-927. [PMID: 29499125 PMCID: PMC6728554 DOI: 10.1177/0022034518759302] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The chronic inflammatory immune response triggered by the infection of the tooth root canal system results in the local upregulation of RANKL, resulting in periapical bone loss. While RANKL has a well-characterized role in the control of bone homeostasis/pathology, it can play important roles in the regulation of the immune system, although its possible immunoregulatory role in infectious inflammatory osteolytic conditions remains largely unknown. Here, we used a mouse model of infectious inflammatory periapical lesions subjected to continuous or transitory anti-RANKL inhibition, followed by the analysis of lesion outcome and multiple host response parameters. Anti-RANKL administration resulted in arrest of bone loss but interfered in the natural immunoregulation of the lesions observed in the untreated group. RANKL inhibition resulted in an unremitting proinflammatory response, persistent high proinflammatory and effector CD4 response, decreased regulatory T-cell (Treg) migration, and lower levels of Treg-related cytokines IL-10 and TGFb. Anti-RANKL blockade impaired the immunoregulatory process only in early disease stages, while the late administration of anti-RANKL did not interfere with the stablished immunoregulation. The impaired immunoregulation due to RANKL inhibition is characterized by increased delayed-type hypersensitivity in vivo and T-cell proliferation in vitro to the infecting bacteria, which mimic the effects of Treg inhibition, reinforcing a possible influence of RANKL on Treg-mediated suppressive response. The adoptive transfer of CD4+FOXp3+ Tregs to mice receiving anti-RANKL therapy restored the immunoregulatory capacity, attenuating the inflammatory response in the lesions, reestablishing normal T-cell response in vivo and in vitro, and preventing lesion relapse upon anti-RANKL therapy cessation. Therefore, while RANKL inhibition efficiently limited the periapical bone loss, it promoted an unremitting host inflammatory response by interfering with Treg activity, suggesting that this classic osteoclastogenic mediator plays a role in immunoregulation.
Collapse
Affiliation(s)
- C.F. Francisconi
- Department of Biological Sciences,
School of Dentistry of Bauru, University of São Paulo, Bauru, Brazil
| | - A.E. Vieira
- Institute of Biological Sciences and
Health, Federal University of Alagoas, Maceió, Brazil
| | - M.C.S. Azevedo
- Department of Biological Sciences,
School of Dentistry of Bauru, University of São Paulo, Bauru, Brazil
| | - A.P. Tabanez
- Department of Biological Sciences,
School of Dentistry of Bauru, University of São Paulo, Bauru, Brazil
| | - A.C. Fonseca
- Department of Biological Sciences,
School of Dentistry of Bauru, University of São Paulo, Bauru, Brazil
| | | | - A. Letra
- Department of Endodontics, School of
Dentistry, University of Texas Health Science Center at Houston, Houston, TX,
USA
- Department of Diagnostic and Biomedical
Sciences and Center for Craniofacial Research, University of Texas Health Science
Center at Houston, Houston, Texas, USA
| | - R.M. Silva
- Department of Endodontics, School of
Dentistry, University of Texas Health Science Center at Houston, Houston, TX,
USA
| | - C.S. Sfeir
- Center for Craniofacial Regeneration,
University of Pittsburgh, Pittsburgh, PA, USA
- McGowan Institute for Regenerative
Medicine, University of Pittsburgh, Pittsburgh, PA, USA
- Department of Periodontics and
Preventive Dentistry, University of Pittsburgh, Pittsburgh, PA, USA
| | - S.R. Little
- Center for Craniofacial Regeneration,
University of Pittsburgh, Pittsburgh, PA, USA
- McGowan Institute for Regenerative
Medicine, University of Pittsburgh, Pittsburgh, PA, USA
- Department of Chemical and Petroleum
Engineering, University of Pittsburgh, Pittsburgh, PA, USA
- Department of Immunology, University
of Pittsburgh, Pittsburgh, PA, USA
- Department of Bioengineering,
University of Pittsburgh, Pittsburgh, PA, USA
| | - G.P. Garlet
- Department of Biological Sciences,
School of Dentistry of Bauru, University of São Paulo, Bauru, Brazil
| |
Collapse
|
16
|
Afolayan FID, Erinwusi B, Oyeyemi OT. Immunomodulatory activity of curcumin-entrapped poly d,l-lactic- co-glycolic acid nanoparticles in mice. Integr Med Res 2018; 7:168-175. [PMID: 29989030 PMCID: PMC6035456 DOI: 10.1016/j.imr.2018.02.004] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2017] [Revised: 02/01/2018] [Accepted: 02/14/2018] [Indexed: 12/21/2022] Open
Abstract
Background Studies have shown that curcumin from Curcuma longa has a wide range of medicinal and immunomodulatory properties. These activities have, however, been hindered by its low bioavailability. Meanwhile, incorporation of nanoparticles has been shown to increase bioavailability of certain drugs. This study was, therefore, conducted to comparatively evaluate the immunomodulatory activity of free and nanoparticulate curcumin in mice. Methods Healthy albino mice were sensitized with sheep red blood cells (SRBCs) and thereafter free and nanoparticulate curcumin were administered orally at doses of 5 mg/kg/day and 10 mg/kg/day for 10 days to the mice. The assessment of the immunomodulatory activity was carried out by determining the humoral and cell-mediated immune responses using hemagglutination and delayed-type hypersensitivity assays, respectively. Hematological components and some lymphoid organs of treated mice were further evaluated. Results The study showed that nanoparticulate curcumin stimulated higher early cell-mediated immune response at 5 mg/kg and 10 mg/kg when compared to control. While nanoparticulate curcumin significantly stimulated primary humoral immune response with 9.00 ± 1.00 antibody titre (p < 0.05), the free curcumin suppressed the immunity with 3.33 ± 0.67 antibody titre when compared to control. Similar result was observed with secondary humoral antibody titres. Production of white blood cells and weight of the lymphoid organs were also enhanced in the groups that received 10 mg/kg nanocurcumin. Conclusion This work showed that poly d,l-lactic-co-glycolic acid entrapped curcumin nanoparticle could increase bioavailability of curcumin for improved immunity.
Collapse
Affiliation(s)
- Funmilayo I D Afolayan
- Cell Biology and Genetics Unit, Department of Zoology, University of Ibadan, Ibadan, Nigeria
| | - Blessing Erinwusi
- Cell Biology and Genetics Unit, Department of Zoology, University of Ibadan, Ibadan, Nigeria
| | - Oyetunde T Oyeyemi
- Department of Biological Sciences, University of Medical Sciences, Ondo, Nigeria
| |
Collapse
|
17
|
Suppression of autoimmune demyelinating disease by preferential stimulation of CNS-specific CD8 T cells using Listeria-encoded neuroantigen. Sci Rep 2017; 7:1519. [PMID: 28484224 PMCID: PMC5431563 DOI: 10.1038/s41598-017-01771-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Accepted: 04/12/2017] [Indexed: 11/16/2022] Open
Abstract
CD8 T-cells predominate in CNS lesions of MS patients and display oligoclonal expansion. However, the role of myelin-specific CD8 T-cells in disease remains unclear, with studies showing protective and pathogenic roles in EAE. We demonstrated a disease-suppressive function for CNS-specific CD8 T-cells in a model where the antigen is exogenously administered in vivo and used for in vitro activation. To probe the nature of the CD8 response elicited by endogenously presented myelin antigens in vivo, we developed a novel approach utilizing infection with Listeria monocytogenes (LM) encoding proteolipid protein peptide (PLP) amino acids 178-191 (LM-PLP). LM-PLP infection preferentially induced PLP-specific CD8 T-cell responses. Despite the induction of PLP-specific CD8 T-cells, LM-PLP infection did not result in disease. In fact, LM-PLP infection resulted in significant amelioration of PLP178-191-induced EAE. Disease suppression was not observed in mice deficient in CD8 T-cells, IFN-γ or perforin. DTH responses and CNS infiltration were reduced in protected mice, and their CD4 T-cells had reduced capacity to induce tissue inflammation. Importantly, infection with LM-PLP ameliorated established disease. Our studies indicate that CD8 T-cells induced by endogenous presentation of PLP178-191 attenuate CNS autoimmunity in models of EAE, implicating the potential of this approach as a novel immunotherapeutic strategy.
Collapse
|
18
|
Di Mario G, Soprana E, Gubinelli F, Panigada M, Facchini M, Fabiani C, Garulli B, Basileo M, Cassone A, Siccardi A, Donatelli I, Castrucci MR. Immunogenicity of modified vaccinia virus Ankara expressing the hemagglutinin stalk domain of pandemic (H1N1) 2009 influenza virus. Pathog Glob Health 2017; 111:69-75. [PMID: 28081672 PMCID: PMC5375617 DOI: 10.1080/20477724.2016.1275464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022] Open
Abstract
BACKGROUND Vaccination offers protection against influenza, although current vaccines need to be reformulated each year. The development of a broadly protective influenza vaccine would guarantee the induction of heterosubtypic immunity also against emerging influenza viruses of a novel subtype. Vaccine candidates based on the stalk region of the hemagglutinin (HA) have the potential to induce broad and persistent protection against diverse influenza A viruses. METHODS Modified vaccinia virus Ankara (MVA) expressing a headless HA (hlHA) of A/California/4/09 (CA/09) virus was used as a vaccine to immunize C57BL/6 mice. Specific antibody and cell-mediated immune responses were determined, and challenge experiments were performed by infecting vaccinated mice with CA/09 virus. RESULTS Immunization of mice with CA/09-derived hlHA, vectored by MVA, was able to elicit influenza-specific broad cross-reactive antibodies and cell-mediated immune responses, but failed to induce neutralizing antibodies and did not protect mice against virus challenge. CONCLUSION Although highly immunogenic, our vaccine was unable to induce a protective immunity against influenza. A misfolded and unstable conformation of the hlHA molecule may have affected its capacity of inducing neutralizing antiviral, conformational antibodies. Design of stable hlHA-based immunogens and their delivery by recombinant MVA-based vectors has the potential of improving this promising approach for a universal influenza vaccine.
Collapse
Affiliation(s)
- Giuseppina Di Mario
- a Department of Infectious Diseases , Istituto Superiore di Sanità , Rome , Italy
| | - Elisa Soprana
- b Molecular Immunology Unit , San Raffaele Research Institute , Milan , Italy
| | - Francesco Gubinelli
- b Molecular Immunology Unit , San Raffaele Research Institute , Milan , Italy
| | - Maddalena Panigada
- b Molecular Immunology Unit , San Raffaele Research Institute , Milan , Italy
| | - Marzia Facchini
- a Department of Infectious Diseases , Istituto Superiore di Sanità , Rome , Italy
| | - Concetta Fabiani
- a Department of Infectious Diseases , Istituto Superiore di Sanità , Rome , Italy
| | - Bruno Garulli
- c Department of Biology and Biotechnology "Charles Darwin" , Sapienza University of Rome , Rome , Italy
| | - Michela Basileo
- d Polo d'Innovazione della Genomica, Genetica e Biologia , University of Perugia , Perugia , Italy
| | - Antonio Cassone
- d Polo d'Innovazione della Genomica, Genetica e Biologia , University of Perugia , Perugia , Italy
| | - Antonio Siccardi
- b Molecular Immunology Unit , San Raffaele Research Institute , Milan , Italy
| | - Isabella Donatelli
- a Department of Infectious Diseases , Istituto Superiore di Sanità , Rome , Italy
| | - Maria R Castrucci
- a Department of Infectious Diseases , Istituto Superiore di Sanità , Rome , Italy
| |
Collapse
|
19
|
Ebrahimnezhad S, Amirghofran Z, Karimi MH. Decline in Immunological Responses Mediated by Dendritic Cells in Mice Treated with 18α-Glycyrrhetinic Acid. Immunol Invest 2016; 45:191-204. [DOI: 10.3109/08820139.2015.1113425] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
20
|
Leukocyte-specific protein 1 regulates T-cell migration in rheumatoid arthritis. Proc Natl Acad Sci U S A 2015; 112:E6535-43. [PMID: 26554018 DOI: 10.1073/pnas.1514152112] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Copy number variations (CNVs) have been implicated in human diseases. However, it remains unclear how they affect immune dysfunction and autoimmune diseases, including rheumatoid arthritis (RA). Here, we identified a novel leukocyte-specific protein 1 (LSP1) deletion variant for RA susceptibility located in 11p15.5. We replicated that the copy number of LSP1 gene is significantly lower in patients with RA, which correlates positively with LSP1 protein expression levels. Differentially expressed genes in Lsp1-deficient primary T cells represent cell motility and immune and cytokine responses. Functional assays demonstrated that LSP1, induced by T-cell receptor activation, negatively regulates T-cell migration by reducing ERK activation in vitro. In mice with T-cell-dependent chronic inflammation, loss of Lsp1 promotes migration of T cells into the target tissues as well as draining lymph nodes, exacerbating disease severity. Moreover, patients with RA show diminished expression of LSP1 in peripheral T cells with increased migratory capacity, suggesting that the defect in LSP1 signaling lowers the threshold for T-cell activation. To our knowledge, our work is the first to demonstrate how CNVs result in immune dysfunction and a disease phenotype. Particularly, our data highlight the importance of LSP1 CNVs and LSP1 insufficiency in the pathogenesis of RA and provide previously unidentified insights into the mechanisms underlying T-cell migration toward the inflamed synovium in RA.
Collapse
|
21
|
Eze CO, Nworu CS, Esimone C, Okore V. Immunomodulatory activities of methanol extract of the whole aerial part of Phyllantus niruri L. ACTA ACUST UNITED AC 2014. [DOI: 10.5897/jpp2013.0305] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
22
|
Lin R, Kim H, Hong J, Li QJ. Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention. ACS Med Chem Lett 2014; 5:485-90. [PMID: 24900866 DOI: 10.1021/ml4004809] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2013] [Accepted: 03/10/2014] [Indexed: 12/31/2022] Open
Abstract
Subglutinol A (1) is an immunosuppressive natural product isolated from Fusarium subglutinans, an endophytic fungus from the vine Tripterygium wilfordii. We show that 1 exerts multimodal immune-suppressive effects on activated T cells in vitro: subglutinol A (1) effectively blocks T cell proliferation and survival while profoundly inhibiting pro-inflammatory IFNγ and IL-17 production by fully differentiated effector Th1 and Th17 cells. Our data further reveal that 1 may exert its anti-inflammatory effects by exacerbating mitochondrial damage in T cells. Additionally, we demonstrate that 1 significantly reduces lymphocytic infiltration into the footpad and ameliorates footpad swelling in the mouse model of Th1-driven delayed-type hypersensitivity. These results suggest the potential of 1 as a novel therapeutic for inflammatory diseases.
Collapse
Affiliation(s)
- Regina Lin
- Department of Immunology, Duke University Medical Center, Durham, North Carolina 27710, United States
| | - Hyoungsu Kim
- Department
of Chemistry, Duke University, Durham, North Carolina 27708, United States
| | - Jiyong Hong
- Department
of Chemistry, Duke University, Durham, North Carolina 27708, United States
- Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, United States
| | - Qi-Jing Li
- Department of Immunology, Duke University Medical Center, Durham, North Carolina 27710, United States
| |
Collapse
|
23
|
Reis EF, Castro SB, Alves CCS, Oliveira EE, Corrêa TA, Almeida MV, Ferreira AP. Lipophilic amino alcohols reduces carrageenan-induced paw edema and anti-OVA DTH in BALB/c mice. Int Immunopharmacol 2013; 17:727-32. [DOI: 10.1016/j.intimp.2013.08.017] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2013] [Revised: 08/12/2013] [Accepted: 08/27/2013] [Indexed: 10/26/2022]
|